Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VACCINEX, INC.VCNX · Entity 9673 | Director | May 11, 2021 | May 12, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VACCINEX, INC.
Report date May 11, 2021 · Filed May 12, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.15 | Direct | 28,586 |
Reported balance
After 2021-05-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-05-11 · Grant · Acquired 28,586 · Balance 28,586 F4: This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 9, 2031 or five years following retirement or cessation of services, whichever occurs first. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.90 · Expires 2023-06-20 | Direct | 6,000 |
Reported balance
Holding disclosure · report date 2021-05-11 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 6,000 F1: Exercisable in full as of the date of this report. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.60 · Expires 2027-09-15 | Direct | 2,239 |
Reported balance
Holding disclosure · report date 2021-05-11 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 2,239 F1: Exercisable in full as of the date of this report. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.78 | Direct | 7,718 |
Reported balance
Holding disclosure · report date 2021-05-11 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 7,718 F2: This option expires on May 14, 2029 or five years following retirement or cessation of services, whichever occurs first. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.95 | Direct | 15,679 |
Reported balance
Holding disclosure · report date 2021-05-11 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 15,679 F3: This option expires on May 12, 2030 or five years following retirement or cessation of services, whichever occurs first. |
| Common StockSEC Table I · non-derivative | Direct | 300 |
Reported balance
Holding disclosure · report date 2021-05-11 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 300 |
Filing footnotes · ownership attribution and instrument terms
F1: Exercisable in full as of the date of this report.
F2: This option expires on May 14, 2029 or five years following retirement or cessation of services, whichever occurs first.
F3: This option expires on May 12, 2030 or five years following retirement or cessation of services, whichever occurs first.
F4: This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 9, 2031 or five years following retirement or cessation of services, whichever occurs first.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
LogicBio Therapeutics, Inc.
Report date November 16, 2022 · Filed November 17, 2022
Section 16 reporting ended · disclosed 2022-11-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.38 · Expires 2032-06-17 | Direct | 0 |
Reported balance
After 2022-11-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-11-16 · Disposition to issuer · Disposed 12,500 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger, dated as of October 3, 2022, by and among the Company, Alexion Pharmaceuticals, Inc. ("Parent") and Camelot Merger Sub, Inc. ("Merger Sub"), on November 16, 2022 (the "Effective Time"), Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation in the Merger and as a wholly-owned subsidiary of Parent, and, at the Effective Time, each option was cancelled pursuant to the terms of the Merger Agreement; provided, that each option with a per share exercise price equal to or greater than $2.07 was automatically cancelled for no consideration. For more information see the Solicitation/Recommendation Statement on Schedule 14D-9 filed by the Company with the United States Securities and Exchange Commission on October 18, 2022. F1: The options were granted on June 17, 2022. The options were scheduled to vest in full on the earlier of (i) the first anniversary of the grant date, and (ii) the day prior to the 2023 Annual Meeting of Stockholders of LogicBio Therapeutics, Inc. (the "Company"), subject to the Reporting Person's continued service with the Company on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted on June 17, 2022. The options were scheduled to vest in full on the earlier of (i) the first anniversary of the grant date, and (ii) the day prior to the 2023 Annual Meeting of Stockholders of LogicBio Therapeutics, Inc. (the "Company"), subject to the Reporting Person's continued service with the Company on the vesting date.
F2: Pursuant to the Agreement and Plan of Merger, dated as of October 3, 2022, by and among the Company, Alexion Pharmaceuticals, Inc. ("Parent") and Camelot Merger Sub, Inc. ("Merger Sub"), on November 16, 2022 (the "Effective Time"), Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation in the Merger and as a wholly-owned subsidiary of Parent, and, at the Effective Time, each option was cancelled pursuant to the terms of the Merger Agreement; provided, that each option with a per share exercise price equal to or greater than $2.07 was automatically cancelled for no consideration. For more information see the Solicitation/Recommendation Statement on Schedule 14D-9 filed by the Company with the United States Securities and Exchange Commission on October 18, 2022.
Surface Oncology, Inc.
Report date September 08, 2023 · Filed September 08, 2023
Section 16 reporting ended · disclosed 2023-09-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-09-08 transaction · row 1
1 source rowRow 1 · 2023-09-08 · Disposition to issuer · Disposed 129,222 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated as of June 15, 2023 (the "Merger Agreement"), by and among the Issuer, Coherus BioSciences, Inc. ("Coherus"), Crimson Merger Sub I, Inc., a direct, wholly owned subsidiary of Coherus ("Merger Sub I"), and Crimson Merger Sub II, LLC, a direct, wholly owned subsidiary of Coherus ("Merger Sub II"), pursuant to which Merger Sub I merged with and into the Issuer effective as of September 8, 2023 (the "Effective Time"), with Surface surviving such merger as a direct, wholly owned subsidiary of Coherus (the "First Merger"), and, as part of the same overall transaction, promptly after the First Merger, the surviving corporation of the First Merger merged with and into Merger Sub II, with Merger Sub II surviving such merger. F2: At the Effective Time, each issued and outstanding share of common stock of the Issuer was cancelled and converted into the right to receive (i) 0.1960 (the "Exchange Ratio") shares of common stock of Coherus and (ii) one contingent value right (each, a "CVR") representing a contractual right to receive contingent future conditional payments pursuant to the terms of a Contingent Value Rights Agreement by and between Coherus and Computershare Inc. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated as of June 15, 2023 (the "Merger Agreement"), by and among the Issuer, Coherus BioSciences, Inc. ("Coherus"), Crimson Merger Sub I, Inc., a direct, wholly owned subsidiary of Coherus ("Merger Sub I"), and Crimson Merger Sub II, LLC, a direct, wholly owned subsidiary of Coherus ("Merger Sub II"), pursuant to which Merger Sub I merged with and into the Issuer effective as of September 8, 2023 (the "Effective Time"), with Surface surviving such merger as a direct, wholly owned subsidiary of Coherus (the "First Merger"), and, as part of the same overall transaction, promptly after the First Merger, the surviving corporation of the First Merger merged with and into Merger Sub II, with Merger Sub II surviving such merger.
F2: At the Effective Time, each issued and outstanding share of common stock of the Issuer was cancelled and converted into the right to receive (i) 0.1960 (the "Exchange Ratio") shares of common stock of Coherus and (ii) one contingent value right (each, a "CVR") representing a contractual right to receive contingent future conditional payments pursuant to the terms of a Contingent Value Rights Agreement by and between Coherus and Computershare Inc.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 08, 2023 Filed Sep 8, 2023 16:00 UTC | Surface Oncology, Inc. SURF · Entity 109857 | Disposition to issuerCommon Stock | 129,222 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-048758 · doc4.xml · nonDerivative · entry 1 Goater Jeff · CIK 0001656435 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated as of June 15, 2023 (the "Merger Agreement"), by and among the Issuer, Coherus BioSciences, Inc. ("Coherus"), Crimson Merger Sub I, Inc., a direct, wholly owned subsidiary of Coherus ("Merger Sub I"), and Crimson Merger Sub II, LLC, a direct, wholly owned subsidiary of Coherus ("Merger Sub II"), pursuant to which Merger Sub I merged with and into the Issuer effective as of September 8, 2023 (the "Effective Time"), with Surface surviving such merger as a direct, wholly owned subsidiary of Coherus (the "First Merger"), and, as part of the same overall transaction, promptly after the First Merger, the surviving corporation of the First Merger merged with and into Merger Sub II, with Merger Sub II surviving such merger. F2 · price: At the Effective Time, each issued and outstanding share of common stock of the Issuer was cancelled and converted into the right to receive (i) 0.1960 (the "Exchange Ratio") shares of common stock of Coherus and (ii) one contingent value right (each, a "CVR") representing a contractual right to receive contingent future conditional payments pursuant to the terms of a Contingent Value Rights Agreement by and between Coherus and Computershare Inc. Read SEC document |
| November 16, 2022 Filed Nov 17, 2022 21:09 UTC | LogicBio Therapeutics, Inc. LOGC · Entity 122292 | Disposition to issuerStock Option (right to buy) · Derivative | 12,500 | Not disclosed Strike: $0.38 | Not disclosed |
DisclosureSEC source: 0000899243-22-036298 · doc4.xml · derivative · entry 1 Goater Jeff · CIK 0001656435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2032-06-17 F2 · price: Pursuant to the Agreement and Plan of Merger, dated as of October 3, 2022, by and among the Company, Alexion Pharmaceuticals, Inc. ("Parent") and Camelot Merger Sub, Inc. ("Merger Sub"), on November 16, 2022 (the "Effective Time"), Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation in the Merger and as a wholly-owned subsidiary of Parent, and, at the Effective Time, each option was cancelled pursuant to the terms of the Merger Agreement; provided, that each option with a per share exercise price equal to or greater than $2.07 was automatically cancelled for no consideration. For more information see the Solicitation/Recommendation Statement on Schedule 14D-9 filed by the Company with the United States Securities and Exchange Commission on October 18, 2022. F1 · derivative.exercise_date: The options were granted on June 17, 2022. The options were scheduled to vest in full on the earlier of (i) the first anniversary of the grant date, and (ii) the day prior to the 2023 Annual Meeting of Stockholders of LogicBio Therapeutics, Inc. (the "Company"), subject to the Reporting Person's continued service with the Company on the vesting date. Read SEC document |
| June 17, 2022 Filed Jun 21, 2022 08:08 UTC | LogicBio Therapeutics, Inc. LOGC · Entity 122292 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001209191-22-038236 · doc4.xml · derivative · entry 1 Goater Jeff · CIK 0001656435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2032-06-17 F1 · shares: The options were granted by LogicBio Therapeutics, Inc. (the "Company") pursuant to its 2018 Equity Incentive Plan, as provided under the Company's current non-employee director compensation policy. F2 · derivative.exercise_date: The options will vest in full on the earlier of (i) the first anniversary of the grant date, and (ii) the day prior to the Company's 2023 Annual Meeting of Stockholders, subject to the Reporting Person's continued service with the Company on the vesting date. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:00 UTC | Surface Oncology, Inc. SURF · Entity 109857 | GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001209191-22-036144 · doc4.xml · derivative · entry 1 Goater Jeff · CIK 0001656435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2032-06-08 F1 · derivative.exercise_date: The Options shall vest in twelve equal monthly installments following the date of grant or, if earlier, upon the date of the next Annual Meeting; provided, however, that all vesting shall cease if the director resigns from the Board of Directors or otherwise ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting. Read SEC document |
| July 21, 2021 Filed Jan 14, 2022 20:30 UTC | Surface Oncology, Inc. SURF · Entity 109857 | SaleCommon Stock | 127,778 | $6.10 | $779,445.80 |
DisclosureSEC source: 0001209191-22-003400 · doc4.xml · nonDerivative · entry 1 Goater Jeff · CIK 0001656435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,222 F1 · kind: Amount reported represents the number of shares sold by the reporting person to cover the tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| June 11, 2021 Filed Jun 11, 2021 20:30 UTC | Surface Oncology, Inc. SURF · Entity 109857 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,273 | $0.00 Strike: $4.14 | $0.00 |
DisclosureSEC source: 0001209191-21-040078 · doc4.xml · derivative · entry 8 Goater Jeff · CIK 0001656435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,831 Underlying: Common Stock · 10,273 shares Expires 2027-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option is fully vested and exercisable as of the date hereof. Read SEC document |
| June 11, 2021 Filed Jun 11, 2021 20:30 UTC | Surface Oncology, Inc. SURF · Entity 109857 | SaleCommon Stock | 15,273 | $7.61 | $116,226.00 |
DisclosureSEC source: 0001209191-21-040078 · doc4.xml · nonDerivative · entry 5 Goater Jeff · CIK 0001656435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,000 F2 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $7.58 to $7.64. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| June 11, 2021 Filed Jun 11, 2021 20:30 UTC | Surface Oncology, Inc. SURF · Entity 109857 | Exercise / conversionCommon Stock | 10,273 | $4.14 | $42,530.22 |
DisclosureSEC source: 0001209191-21-040078 · doc4.xml · nonDerivative · entry 4 Goater Jeff · CIK 0001656435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,273 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 11, 2021 Filed Jun 14, 2021 20:01 UTC | LogicBio Therapeutics, Inc. LOGC · Entity 122292 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $4.59 | $0.00 |
DisclosureSEC source: 0001209191-21-040429 · doc4.xml · derivative · entry 1 Goater Jeff · CIK 0001656435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2031-06-11 F1 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2018 Equity Incentive Plan as provided under the Company's compensation policy for non-employee directors. All of the options will vest and become exercisable on the earlier of (i) the first anniversary of the grant date, and (ii) the day prior to the Company's 2022 annual meeting of stockholders, subject to the Reporting Person's continuous service with the Issuer through the vesting date. Read SEC document |
| June 10, 2021 Filed Jun 11, 2021 20:30 UTC | Surface Oncology, Inc. SURF · Entity 109857 | Exercise / conversionStock Option (Right to Buy) · Derivative | 34,727 | $0.00 Strike: $4.14 | $0.00 |
DisclosureSEC source: 0001209191-21-040078 · doc4.xml · derivative · entry 7 Goater Jeff · CIK 0001656435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,325 Underlying: Common Stock · 34,727 shares Expires 2027-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments after the closing of the Issuer's initial public offering. Read SEC document |
| June 10, 2021 Filed Jun 11, 2021 20:30 UTC | Surface Oncology, Inc. SURF · Entity 109857 | Exercise / conversionStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $4.14 | $0.00 |
DisclosureSEC source: 0001209191-21-040078 · doc4.xml · derivative · entry 6 Goater Jeff · CIK 0001656435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,104 Underlying: Common Stock · 200,000 shares Expires 2027-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option is fully vested and exercisable as of the date hereof. Read SEC document |
| June 10, 2021 Filed Jun 11, 2021 20:30 UTC | Surface Oncology, Inc. SURF · Entity 109857 | SaleCommon Stock | 234,727 | $7.66 | $1,798,619.11 |
DisclosureSEC source: 0001209191-21-040078 · doc4.xml · nonDerivative · entry 3 Goater Jeff · CIK 0001656435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,000 F1 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $7.56 to $7.82. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| June 10, 2021 Filed Jun 11, 2021 20:30 UTC | Surface Oncology, Inc. SURF · Entity 109857 | Exercise / conversionCommon Stock | 34,727 | $4.14 | $143,769.78 |
DisclosureSEC source: 0001209191-21-040078 · doc4.xml · nonDerivative · entry 2 Goater Jeff · CIK 0001656435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 496,727 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 10, 2021 Filed Jun 11, 2021 20:30 UTC | Surface Oncology, Inc. SURF · Entity 109857 | Exercise / conversionCommon Stock | 200,000 | $4.14 | $828,000.00 |
DisclosureSEC source: 0001209191-21-040078 · doc4.xml · nonDerivative · entry 1 Goater Jeff · CIK 0001656435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 462,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2021 Filed May 12, 2021 16:27 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 28,586 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0000891839-21-000140 · edgar.xml · derivative · entry 6 Goater Jeff · CIK 0001656435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,586 Underlying: Common Stock · 28,586 shares Expires not disclosed F4 · derivative.expiration_date: This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 9, 2031 or five years following retirement or cessation of services, whichever occurs first. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 20:25 UTC | Surface Oncology, Inc. SURF · Entity 109857 | GrantStock Option (Right to Buy) · Derivative | 4,425 | $0.00 Strike: $8.09 | $0.00 |
DisclosureSEC source: 0001209191-21-024886 · doc4.xml · derivative · entry 4 Goater Jeff · CIK 0001656435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,425 Underlying: Common Stock · 4,425 shares Expires 2031-04-01 F4 · derivative.exercise_date: This option shall vest monthly from April 1, 2022 through the earlier of (i) June 30, 2022 and (ii) the last date of reporting person's Service Relationship. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 20:25 UTC | Surface Oncology, Inc. SURF · Entity 109857 | GrantStock Option (Right to Buy) · Derivative | 35,400 | $0.00 Strike: $8.09 | $0.00 |
DisclosureSEC source: 0001209191-21-024886 · doc4.xml · derivative · entry 3 Goater Jeff · CIK 0001656435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,400 Underlying: Common Stock · 35,400 shares Expires 2031-04-01 F3 · derivative.exercise_date: This option shall vest in full on March 31, 2022; subject to the reporting person's Service Relationship on such date. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 20:25 UTC | Surface Oncology, Inc. SURF · Entity 109857 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $8.09 | $0.00 |
DisclosureSEC source: 0001209191-21-024886 · doc4.xml · derivative · entry 2 Goater Jeff · CIK 0001656435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-04-01 F2 · derivative.exercise_date: This option vests monthly through the earlier of (i) March 31, 2022 and (ii) the last date of the reporting person's last day of their Service Relationship. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 20:25 UTC | Surface Oncology, Inc. SURF · Entity 109857 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $8.09 | $0.00 |
DisclosureSEC source: 0001209191-21-024886 · doc4.xml · derivative · entry 1 Goater Jeff · CIK 0001656435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-04-01 F1 · derivative.exercise_date: This option vests monthly through the earlier of (i) September 30, 2021 and (ii) the last date of the reporting person's last day of their Service Relationship Read SEC document |
| February 08, 2021 Filed Feb 9, 2021 20:00 UTC | Surface Oncology, Inc. SURF · Entity 109857 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $3.18 | $0.00 |
DisclosureSEC source: 0001209191-21-009056 · doc4.xml · derivative · entry 3 Goater Jeff · CIK 0001656435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,000 Underlying: Common Stock · 2,500 shares Expires 2030-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option shall become exercisable in equal monthly installments over four years following January 21, 2020, so long as the reporting person remains an employee or other service provider of the Company on such dates. Read SEC document |
| February 08, 2021 Filed Feb 9, 2021 20:00 UTC | Surface Oncology, Inc. SURF · Entity 109857 | SaleCommon Stock | 2,500 | $12.50 | $31,250.00 |
DisclosureSEC source: 0001209191-21-009056 · doc4.xml · nonDerivative · entry 2 Goater Jeff · CIK 0001656435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 18, 2020. Read SEC document |
| February 08, 2021 Filed Feb 9, 2021 20:00 UTC | Surface Oncology, Inc. SURF · Entity 109857 | Exercise / conversionCommon Stock | 2,500 | $3.18 | $7,950.00 |
DisclosureSEC source: 0001209191-21-009056 · doc4.xml · nonDerivative · entry 1 Goater Jeff · CIK 0001656435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 20:00 UTC | Surface Oncology, Inc. SURF · Entity 109857 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $3.18 | $0.00 |
DisclosureSEC source: 0001209191-21-007550 · doc4.xml · derivative · entry 3 Goater Jeff · CIK 0001656435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,500 Underlying: Common Stock · 2,500 shares Expires 2030-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option shall become exercisable in equal monthly installments over four years following January 21, 2020, so long as the reporting person remains an employee or other service provider of the Company on such dates. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 20:00 UTC | Surface Oncology, Inc. SURF · Entity 109857 | SaleCommon Stock | 2,500 | $10.69 | $26,717.50 |
DisclosureSEC source: 0001209191-21-007550 · doc4.xml · nonDerivative · entry 2 Goater Jeff · CIK 0001656435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 18, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.32 to $11.19, inclusive. The reporting person undertakes to provide to Surface Oncology, Inc., any security holder of Surface Oncology, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 20:00 UTC | Surface Oncology, Inc. SURF · Entity 109857 | Exercise / conversionCommon Stock | 2,500 | $3.18 | $7,950.00 |
DisclosureSEC source: 0001209191-21-007550 · doc4.xml · nonDerivative · entry 1 Goater Jeff · CIK 0001656435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 20:17 UTC | Surface Oncology, Inc. SURF · Entity 109857 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $3.18 | $0.00 |
DisclosureSEC source: 0001209191-21-004767 · doc4.xml · derivative · entry 3 Goater Jeff · CIK 0001656435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,000 Underlying: Common Stock · 5,000 shares Expires 2030-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option shall become exercisable in equal monthly installments over four years following January 21, 2020, so long as the reporting person remains an employee or other service provider of the Company on such dates. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 20:17 UTC | Surface Oncology, Inc. SURF · Entity 109857 | SaleCommon Stock | 5,000 | $13.00 | $65,000.00 |
DisclosureSEC source: 0001209191-21-004767 · doc4.xml · nonDerivative · entry 2 Goater Jeff · CIK 0001656435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 18, 2020. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 20:17 UTC | Surface Oncology, Inc. SURF · Entity 109857 | Exercise / conversionCommon Stock | 5,000 | $3.18 | $15,900.00 |
DisclosureSEC source: 0001209191-21-004767 · doc4.xml · nonDerivative · entry 1 Goater Jeff · CIK 0001656435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 10, 2020 Filed Dec 14, 2020 16:45 UTC | LogicBio Therapeutics, Inc. LOGC · Entity 122292 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $7.36 | $0.00 |
DisclosureSEC source: 0000899243-20-033746 · doc4.xml · derivative · entry 1 Goater Jeff · CIK 0001656435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-12-10 F1 · derivative.exercise_date: The option becomes exercisable in equal installments on each of the first three anniversaries of the grant date, December 10, 2020. Read SEC document |
| May 14, 2020 Filed May 18, 2020 16:22 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 15,679 | $0.00 Strike: $3.95 | $0.00 |
DisclosureSEC source: 0000891839-20-000121 · edgar.xml · derivative · entry 5 Goater Jeff · CIK 0001656435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,679 Underlying: Common Stock · 15,679 shares Expires not disclosed F3 · derivative.expiration_date: This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 12, 2030 or five years following retirement or cessation of services, whichever occurs first. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 16:05 UTC | Surface Oncology, Inc. SURF · Entity 109857 | PurchaseCommon Stock | 5,000 | $3.23 | $16,150.00 |
DisclosureSEC source: 0001209191-20-007470 · doc4.xml · nonDerivative · entry 1 Goater Jeff · CIK 0001656435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,000 Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 16:05 UTC | Surface Oncology, Inc. SURF · Entity 109857 | GrantStock Option (Right to Buy) · Derivative | 257,000 | $0.00 Strike: $3.18 | $0.00 |
DisclosureSEC source: 0001209191-20-006844 · doc4.xml · derivative · entry 2 Goater Jeff · CIK 0001656435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,000 Underlying: Common Stock · 257,000 shares Expires 2030-02-03 F2 · derivative.exercise_date: This option shall become exercisable in equal monthly installments over four years following January 21, 2020, so long as the reporting person remains an employee or other service provider of the Company on such dates. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 16:05 UTC | Surface Oncology, Inc. SURF · Entity 109857 | GrantCommon Stock | 257,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-006844 · doc4.xml · nonDerivative · entry 1 Goater Jeff · CIK 0001656435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,000 F1 · kind: The shares were acquired pursuant to a restricted stock unit award under the 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in full on the date 18 months after January 21, 2020, so long as the reporting person remains an employee or other service provider of the Company on such date. Read SEC document |
| May 15, 2019 Filed May 17, 2019 17:49 UTC | VACCINEX, INC. VCNX · Entity 9673 | GrantStock Option (Right to Buy) · Derivative | 7,718 | $0.00 Strike: $7.78 | $0.00 |
DisclosureSEC source: 0000891839-19-000076 · edgar.xml · derivative · entry 4 Goater Jeff · CIK 0001656435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,718 Underlying: Common Stock · 7,718 shares Expires not disclosed F2 · derivative.expiration_date: This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 14, 2029 or five years following retirement or cessation of services, whichever occurs first. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 18:03 UTC | Surface Oncology, Inc. SURF · Entity 109857 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $4.27 | $0.00 |
DisclosureSEC source: 0001209191-19-015868 · doc4.xml · derivative · entry 1 Goater Jeff · CIK 0001656435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2029-03-01 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments after February 12, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.